Please assess the completion status of the following clinical trial:

Trial Title: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed mantle cell lymphoma (MCL); the diagnosis must be confirmed by NCCTG pre-registration pathology review by Dr. Paul Kurtin or his designate; it is recommended that the biopsy be an excisional biopsy, but adequate core-needle biopsies will be accepted as long as they are considered adequate for registration by Dr. Kurtin or his designate; the tumor must be cyclin D-1 positive by immunohistochemistry or have evidence of a t(11;14) translocation by fluorescence based in situ hybridization (FISH) or cytogenetics~* Measurable or assessable disease, defined as at least one of the following:~  * A lymph node or tumor mass that is \>= 2.0 cm in at least one dimension by positron emission tomography (PET)/computed tomography (CT), CT, magnetic resonance imaging (MRI), or plain radiograph imaging~ * Splenic enlargement may be used as a measurable parameter if the spleen is palpable \>= 3 cm below the left costal margin~ * Diffuse infiltration of an organ such as the stomach, bone marrow, peripheral blood, liver, lungs, or bowel by lymphoma without a discrete mass would constitute assessable, but not measurable, disease~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, 2, or 3~* Life expectancy \>= 12 weeks~* Absolute neutrophil count (ANC) \>= 1,500/mm³~* Platelet count (PLT) \>= 100,000/mm³~* Serum creatinine =\< 2.0 mg/dL~* Serum total bilirubin (or direct bilirubin if total is abnormal) =\< institutional upper limit of normal (ULN) with or without secondary liver involvement~* Serum glutamic oxaloacetic transaminase (SGOT) =\< 3 x institutional ULN (exception: if there is liver involvement, SGOT must be =\< 5 x institutional ULN)~* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only~* Willingness to return to NCCTG enrolling institution for follow-up~* Willingness to provide the blood specimens as required by the protocol~* Willingness to provide tissue specimens as required by the protocol~* Willing to return to NCCTG enrolling institution for follow-up~* Willing to provide blood and tissue specimens as required by the protocol~* Willing to abstain from eating grapefruit or drinking grapefruit juice~* Willingness to abstain from eating grapefruit or drinking grapefruit juice for the duration of the study~Exclusion Criteria~* Any prior therapy for mantle cell non-Hodgkin lymphoma including radiation therapy; exception: patient may have undergone a splenectomy for diagnosis, cytopenia, or systematic splenomegaly~* Active or uncontrolled infection~* Any of the following cardiac conditions:~  * Uncontrolled high blood pressure~ * Unstable angina~ * Active congestive heart failure~ * Myocardial infarction =\< 6 months~ * Serious uncontrolled cardiac arrhythmia~* Known central nervous system (CNS) involvement~* Any of the following:~  * Pregnant women or women of reproductive ability who are unwilling to use effective contraception while taking the drug and for 12 months after stopping treatment~ * Nursing women~ * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 12 months after stopping treatment~* Medical or psychiatric conditions which, in the opinion of the investigator, make the patient a poor risk for participation~* Known to be human immunodeficiency virus (HIV) positive; HIV testing is not required but should be done if clinically indicated; HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study~* Concurrent malignancy =\< 5 years ago; exceptions: carcinoma in situ of the cervix, resected basal cell or squamous cell carcinomas of the skin, or prostate cancer that is in remission following a radical retropubic prostatectomy or radiation therapy; if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer~* Known hypersensitivity to rituximab or its components, or to murine proteins~* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm~* Prior treatment with an mTOR inhibitor~* Autologous or allogeneic stem cell transplant planned as part of initial therapy~* Receiving enzyme-inducing antiepileptic drugs (enzyme inducing anti-epileptic drugs \[EIAEDs\]; e.g., phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, phenobarbital, or primidone); any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer such as rifampin, glucocorticoids at greater than adrenal replacement levels, or St. John's wort; or receiving strong CYP3A4 inhibitors \* Note: if these agents are discontinued, temsirolimus therapy can begin \>= 7 days after discontinuation of such agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (rituximab, cladribine, temsirolimus) (Type: EXPERIMENTAL): Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).